ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

2014 ASH Annual Meeting and Exposition

The 56th American Society of Hematology (ASH) Annual meeting held in San Francisco from December 6-9.

Adding Sorafenib to Chemo Increases Event-Free Survival in ALL

Adding Sorafenib to Chemo Increases Event-Free Survival in ALL

Dennis Bittner, PhD

BCL-2 Inhibitor Elicits Responses in Pretreated AML

BCL-2 Inhibitor Elicits Responses in Pretreated AML

Brentuximab Vedotin/Bendamustine Combo Shows Activity in Hodgkin Lymphoma

Brentuximab Vedotin/Bendamustine Combo Shows Activity in Hodgkin Lymphoma

CAR T-Cell Therapy for ALL

CAR T-Cell Therapy for ALL

Jae Park, MD

Brentuximab Vedotin in Combination With Bendamustine for Patients With Hodgkin Lymphoma

Brentuximab Vedotin in Combination With Bendamustine for Patients With Hodgkin Lymphoma

Ann S. LaCasce, MD

AG-221 Sparks Durable Remissions in IDH2-Mutated AML

AG-221 Sparks Durable Remissions in IDH2-Mutated AML

Beth Fand Incollingo

Autologous Transplantation Effective, Safe for HIV-Associated Lymphoma

Autologous Transplantation Effective, Safe for HIV-Associated Lymphoma

Silas Inman

Nilotinib Efficacious in Elderly Patients With Philadelphia-Positive ALL

Nilotinib Efficacious in Elderly Patients With Philadelphia-Positive ALL

Andrew J. Roth

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.